A biomedical research can be excused for the confusion about the National Institutes of Health (NIH) as its relationship to the beneficiary companies profit. On the one hand, NIH has invested billions in translational research, and should launch the 50 million new dollars curing Acceleration Network in 2011. On the other hand, proposed new rules for beneficiaries seeking NIH to closely monitor all the links between university researchers and industry partners involved in moving from laboratory to patient treatment.
He announced in May, the state has proposed rules that NIH-funded scientists must fully disclose virtually all financial ties with industry, including travel reimbursement, the cost of speaking and consulting fees, that could be perceived as an attack on the objectivity of research.
Nobody - and certainly not the NIH - not arguing that economic ties with university researchers and companies that are present in biomedical must be broken. Communicate the new rules, the director of NIH Francis Collins and his colleague Sally Rocky recognized American Medical Association Journal editorial that the partnership between researchers and companies are "essential." But they wrote, 'Plain and simple, Americans do not want conflict of interest (FCOIII) affect a federally funded research.'
No comments:
Post a Comment